ArticleScientific reports2026
Post-COVID-19 surge in Guillain-Barré syndrome during the Omicron wave in China with clinical characteristics and potential immune-mediated pathways.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This multicenter study investigated the epidemiological and clinical characteristics of Guillain-Barré syndrome (GBS) during China's Omicron wave (December 2022-February 2023), and compared the number of GBS hospitalizations with the historical data for the same period from 2018 to 2022. A retrospective analysis was conducted at two tertiary hospitals, categorizing patients into COVID-GBS (case group) and Non-COVID-GBS (control group). During the Omicron wave, the number of GBS hospitalizations was 1.5 times higher compared to the period of 2018-2019 (99 cases vs. 66 cases). Poisson regression analysis confirmed a significant increase in GBS incidence during the Omicron wave (December 2022-February 2023) compared to the 2018-2019 baseline period, with an IRR of 1.541 (95% CI: 1.123-2.129, p = 0.0079). COVID-19-associated GBS patients were significantly older (54.04 vs. 42.06 years, p = 0.002) and exhibited higher rates of cranial nerve involvement (p = 0.014), particularly bulbar involvement (p = 0.009). Acute severity was greater in COVID-19-associated cases, evidenced by elevated ICU admissions, higher peak GBS disability scores (p = 0.048), increased mechanical ventilation needs, and one fatality. The median latency from COVID-19 infection to neurological onset was 9.5 days (IQR: 8-14). Despite these acute differences, 6-month disability outcomes showed no significant divergence between groups, suggesting similar long-term prognoses. The surge in GBS incidence aligns with broader reports of elevated GBS rates during COVID-19 surges, though mechanistic links may involve immune-mediated pathways rather than direct viral causation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.